SCHEMBL18323503

SCHEMBL18323503

CC(=O)c1cccc(NC(=O)c2cc(Br)c(S(N)(=O)=O)cn2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.49
▸ NPC1 O15118 6/20 0.49
▸ RAB9A P51151 6/20 0.49
▸ SMN1; SMN2 Q16637 6/20 0.49
▸ TP53 P04637 3/20 0.49
▸ GAA P10253 1/20 0.49
▸ POLB P06746 1/20 0.48
▸ MAPT P10636 3/20 0.47
▸ HPGD P15428 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ LMNA P02545 3/20 0.46
▸ CA1 P00915 4/20 0.46
▸ CA2 P00918 4/20 0.46
▸ CA12 O43570 2/20 0.46
▸ CA9 Q16790 2/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.45
▸ CACNA1B Q00975 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15907194 0.83 ALDH1A1 (0.53) ALDH1A1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL18323128 0.80 NPC1 (0.52) ALDH1A1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL18323294 0.80 NPC1 (0.49) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL18323166 0.76 TP53 (0.38) ALDH1A1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL18323203 0.76 RAB9A (0.44) ALDH1A1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL13210583 0.76 ALDH1A1 (0.79) ALDH1A1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL18323504 0.73 CA1 (0.34) ALDH1A1NPC1RAB9ASMN1; SMN2POLB
SCHEMBL8103599 0.70 CA2 (0.47) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL18323502 0.69 SCN10A (0.49) NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL13210704 0.69 KMT2A (0.81) ALDH1A1NPC1RAB9ASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 — — US disclosed
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 — — US disclosed
Send feedback